For over three decades, CEI has advocated health care reforms that put more power in the hands of consumers to choose their health providers, treatment protocols, and scope of insurance coverage. We have advocated reform of the Food and Drug Administration’s drug and device approval process to allow for greater flexibility and patient choice. And in 2013, CEI organized the court challenges to Obamacare’s exchange subsidies that concluded with the Supreme Court’s King v. Burwell decision.
Healthcare Issue Areas
Featured Posts
Washington Times
Better late than never: New York Times finally admits school shutdowns hurt children
The New York Times has made a “startling” discovery. Its editorial board has recognized that “school closures that took 50 million children out of classrooms…
City Journal
Not-So-Affordable Care
In a 2022 book, Seemed Like a Good Idea, health economist Mark Pauly and his University of Pennsylvania coauthors describe how health-care policymakers “often rely on…
News Release
CEI leads coalition calling on Congress to repeal drug price control provisions of the Inflation Reduction Act
The Competitive Enterprise Institute (CEI) and a coalition 43 conservative and free market groups sent a letter to Congress today calling for the…
Search Posts
City Journal
Equity vs. Evidence
The U.S. Preventive Services Task Force—a volunteer panel of national experts in prevention and evidence-based medicine that makes recommendations for clinical preventive services such as…
National Review
Restricting Pharmacy Benefit Managers Could Decrease Competition and Increase Drug Costs
Congress is considering multiple bills that aim to restrict the ability of pharmacy benefit managers (PBMs) to negotiate discounts and rebates and to require the PBMs…
PCMA
Just the Facts: Research and Analysis Finds Anti-PBM Legislation Does Not Lower Prescription Drug Costs for Patients
PCMA cites CEI’s Joel Zinberg anti PBM legislation: “This policy would significantly change drug pricing and utilization and shift billions of dollars annually from patients…
Wall Street Journal
Court to FDA: Stop Playing Doctor
The Food and Drug Administration regulates pharmaceuticals, but it has no business playing doctor and giving you medical advice. That’s the message of a Sept.
News Release
Congressional Efforts to Regulate PBMs Risk Higher Drug Costs, Worse Health Outcomes for Patients
Pharmacy Benefit Managers (PBMs) are private businesses that developed in the free market to manage prescription drug benefits for health insurance plan sponsors. Nearly all…
Study
A Free Market Solution for Drug Distribution
Executive summary This paper describes and explains the function of Pharmacy Benefit Managers (PBMs) in the American health care economy. PBMs are private businesses that…
